Hormone Replacement Therapy (HRT) — Pharmacology in Detail

1. Rationale and Definition

HRT (also called menopausal hormone therapy, MHT) is administration of estrogen, alone or combined with a progestin, to replace ovarian hormone secretion lost after natural or surgical menopause. At menopause, loss of estrogen produces hot flushes, sweating, psychic disturbances, irritability, fatigue, vaginal atrophy, and accelerated bone loss - Guyton and Hall Textbook of Medical Physiology, p. 1027. HRT reverses these symptoms by restoring estrogen (and, when the uterus is present, a progestin to protect the endometrium).

2. Drug Components

A. Estrogens

Type	Examples	Route
Conjugated equine estrogens (CEE)	Premarin	Oral
Micronized 17β-estradiol	Estrace, various patches/gels	Oral, transdermal
Esterified estrogens	Estropipate	Oral
Synthetic estrogen	Ethinyl estradiol (mainly in contraceptives, higher potency, more hepatic effect)	Oral
Vaginal estrogens	Estradiol ring/cream/tablet	Local

Estrogens act via nuclear estrogen receptors ERα and ERβ, which have differing tissue distributions (ERα predominates in uterus/breast, ERβ in bone/cardiovascular tissue/brain), producing genomic effects (transcriptional regulation) and rapid non-genomic membrane-receptor effects.

B. Progestins

Added in women with an intact uterus to oppose estrogen-driven endometrial proliferation and prevent endometrial hyperplasia/carcinoma.

Medroxyprogesterone acetate (MPA) - most studied (used in WHI trial)
Micronized (natural) progesterone - more favorable lipid/breast profile, less androgenic
Norethindrone acetate
Drospirenone (fourth-generation, antimineralocorticoid activity)

The Textbook of Family Medicine 9e notes progestins have evolved across four generations, with second-generation agents (e.g., MPA) mainly used in postmenopausal hormone therapy - Textbook of Family Medicine 9e, p. 631.

C. Combination and alternative agents

Tibolone: a synthetic steroid with combined estrogenic, progestogenic, and weak androgenic activity - used in some countries as an alternative to standard HRT.
SERMs (selective estrogen receptor modulators): raloxifene acts as an estrogen agonist on bone and liver but an antagonist on breast and is inactive on the uterus; used for osteoporosis rather than vasomotor symptoms, and carries a VTE risk - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1084.
Bazedoxifene + conjugated estrogens: a tissue-selective estrogen complex that pairs a SERM with CEE to protect the endometrium without a progestin.

3. Pharmacokinetics and Routes of Administration

Route determines first-pass hepatic metabolism and clinical risk profile:

Oral estrogens undergo extensive hepatic first-pass metabolism, increasing hepatic synthesis of clotting factors, SHBG, and triglycerides - this raises thromboembolic risk relative to non-oral routes.
Transdermal (patch/gel) estrogen bypasses first-pass hepatic metabolism, giving more stable serum levels and a lower risk of venous thromboembolism (VTE) and possibly stroke. Firestein & Kelley's Textbook of Rheumatology explicitly recommends transdermal estrogen in women with increased coagulation risk - Firestein & Kelley's Textbook of Rheumatology, 2-Vol Set, p. 2798.
Vaginal (cream, tablet, ring): low systemic absorption, used specifically for genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs) with minimal systemic risk; progestin co-therapy generally not required at these low doses.
Injectable/implant: less commonly used now.

4. Regimens

Estrogen-only therapy: for women without a uterus (post-hysterectomy).
Combined estrogen-progestin therapy: for women with an intact uterus, to prevent endometrial hyperplasia/cancer.
- Cyclic (sequential) regimen: estrogen daily, progestin added 10-14 days/month - produces a withdrawal bleed, often used in early menopause/perimenopause.
- Continuous-combined regimen: both hormones daily without a break - aims for amenorrhea, generally used ≥1 year post-menopause.

5. Indications

Moderate-to-severe vasomotor symptoms (hot flushes, night sweats) - the primary approved indication.
Genitourinary syndrome of menopause (local vaginal estrogen).
Prevention of postmenopausal osteoporosis in women with vasomotor symptoms who cannot tolerate other agents (estrogen inhibits bone resorption and reduces fracture risk) - Firestein & Kelley's Textbook of Rheumatology, p. 2755.
Premature ovarian insufficiency/early surgical menopause - continued until at least the natural age of menopause to protect bone and cardiovascular health.

6. Contraindications

Undiagnosed abnormal vaginal bleeding
Known, suspected, or history of breast cancer or other estrogen-dependent malignancy
Active or history of VTE, stroke, or coronary heart disease
Active liver disease
Pregnancy
Known thrombophilic disorder

7. Adverse Effects — The Evidence Base (WHI and HERS)

Two landmark trials reshaped HRT prescribing:

HERS (Heart and Estrogen/Progestin Replacement Study, 1998): secondary-prevention trial in women with existing coronary disease given CEE 0.625 mg + MPA 2.5 mg vs placebo - showed no reduction in cardiac events, and an early increase in cardiac risk, likely due to increased coagulability - Firestein & Kelley's Textbook of Rheumatology, p. 2766.
Women's Health Initiative (WHI): ~162,000 women aged 50-79 randomized to placebo, combined HRT (uterus intact), or estrogen-only (post-hysterectomy). Stopped early due to increased risk. Per 10,000 women treated for one year, the combined HRT arm showed: +7 cardiac events, +8 invasive breast cancers, +8 strokes, +8 pulmonary emboli, but -6 colorectal cancers and -5 hip fractures - Firestein & Kelley's Textbook of Rheumatology, p. 2781. Notably, the estrogen-only arm (no uterus) did not show increased breast cancer or heart disease risk.

Other adverse effects: breast tenderness, bloating, nausea, headache, mood changes, gallbladder disease (more with oral route), and in women with intact uterus, unopposed estrogen increases endometrial hyperplasia/cancer risk (mitigated by adding a progestin).

8. The "Timing Hypothesis" / Window of Opportunity

More recent analyses (post-WHI reanalysis by age/time-since-menopause) suggest risk-benefit is age- and timing-dependent: starting HRT before age 60 or within 10 years of menopause onset is associated with a more favorable benefit-to-risk ratio (less coronary and all-cause mortality risk) than starting later - Guyton and Hall Textbook of Medical Physiology, p. 1027. Current general guidance:

Use the lowest effective dose for the shortest duration needed to control symptoms.
Reassess need annually; there is no arbitrary stop date, but risks generally rise with age/duration of use.
Prefer transdermal estrogen in women with elevated baseline VTE/stroke risk.
Micronized progesterone is generally preferred over MPA when a progestin is needed, given a more neutral breast/cardiovascular profile in observational data (note: still an evolving evidence area).

9. Monitoring

Baseline and periodic evaluation should include blood pressure, breast exam/mammography per screening guidelines, and assessment for unscheduled bleeding (which requires endometrial evaluation).

Recent evidence to flag

Systematic reviews/meta-analyses from the last 2-3 years continue to explore areas of uncertainty:

Cardiovascular risk of HRT specifically in diabetic menopausal women (PMID: 39387240)
HRT and heart failure risk (PMID: 39375997)
Quality appraisal of current HRT clinical practice guidelines using AGREE II (PMID: 39515127)
HRT and Alzheimer's disease - risk factor vs. therapeutic option debate (PMID: 36834617)

None of these overturn the core WHI-based framework above, but they refine risk stratification (e.g., diabetes, heart failure) - worth reviewing if you're managing a specific patient population.

Let me know if you'd like me to go deeper into any single piece - e.g., detailed comparison of estrogen/progestin formulations, management of specific patient subgroups (diabetic, high VTE risk, breast cancer survivors), or the pharmacology of SERMs/tibolone as alternatives.

This is a shared conversation. Sign in to Orris to start your own chat.